TMCI Stock Dives 43.8% Amid Q3 10-Q Filing and Governance Update
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a medical technology company headquartered in Ponte Vedra Beach, Florida. Founded in 2014, the company specializes in the surgical management of bunion (hallux valgus) and related midfoot deformities. Its primary offering, the Lapiplasty® 3D Bunion Correction® System, corrects the metatarsal bone in all three planes and secures the unstable joint. Additional products include the Adductoplasty® Midfoot Correction System, SpeedMTP™ Rapid Compression Implant, Nanoplasty™ and Percuplasty™ minimally invasive systems, the SpeedPlate™ fixation platform, and a Hammertoe PEEK Fixation System.
Corporate Structure and Workforce
According to LinkedIn data, Treace employs between 201 and 500 people in various functions, including research and development, sales training, regulatory affairs, clinical support, and manufacturing. Key departments include:
- Research & Development: Focused on the design and clinical evaluation of new implants and instruments
- Commercial: Responsible for sales training, regional field teams, and surgeon education
- Regulatory & Quality: Ensures compliance with FDA and international medical device standards
- Operations: Handles manufacturing, supply chain, and logistics
Bunion surgery by JAFAR AHMED
Recent Developments and News
- November 6, 2025: Treace filed its Form 10-Q for the quarter ended September 30, 2025, with the U.S. Securities and Exchange Commission, detailing quarterly revenue, expense trends, and management’s discussion of operating results.
- November 6, 2025: The company submitted a Current Report on Form 8-K (Items 2.02, 5.02, 9.01), which included updates on corporate governance and financial statement exhibits.
- August 15, 2025: An Amendment to Schedule 13G/A reported that Armistice Capital, LLC holds 6,260,000 shares, or 9.91% of Treace’s common stock, with shared voting and dispositive power.
- November 6, 2025: On the Nasdaq, TMCI closed at $3.50 per share, down 43.82% from its prior close of $6.25, with a trading volume of 2,289,184 shares.
Financial and Strategic Analysis
As of September 30, 2025, trailing-twelve-month (TTM) financial figures obtained from public filings and market data include:
| Metric | Value |
|---|---|
| Revenue (TTM) | $213.75 million |
| Net Income (TTM) | –$49.18 million |
| Diluted EPS (TTM) | –$0.79 |
| Gross Profit Margin | (Data not disclosed) |
| Profit Margin | –23.01% |
| Total Cash (MRQ) | $69.29 million |
| Total Debt/Equity (MRQ) | 71.81% |
| Market Capitalization (Nov 6) | ~$395 million |
| Beta (5Y Monthly) | 0.69 |
Management continues to invest in product innovation while managing operating expenses. The 10-Q highlights R&D spending and cost-control measures aimed at expanding procedure volumes and clinical evidence. The presence of a significant shareholder—Armistice Capital at 9.91%—may have implications for strategic priorities or board composition.
Market Position and Industry Context
Bunion deformities affect an estimated 67 million Americans, with approximately 1.1 million surgical candidates annually. Treace operates within the broader healthcare sector’s medical appliances and equipment category. Its 3D correction approach addresses the underlying metatarsal pronation, distinguishing it from traditional osteotomy products. Competing devices come from established orthopedic firms, but Treace’s patent-protected platforms and the performance of over 130,000 Lapiplasty procedures position it as a specialized player in foot and ankle surgery. The company’s shares trade at a price-to-sales ratio of approximately 1.83 and a price-to-book ratio of 4.05.
tl;dr
On November 6, 2025, TMCI shares closed at $3.50, down 43.82%, amid increased trading volume. The company filed its Q3 2025 10-Q and an 8-K detailing governance updates. Armistice Capital reported ownership of 9.91%. TTM revenue stands at $213.75 million with a net loss of $49.18 million. Management's focus includes next-generation minimally invasive systems and expanded global surgeon education programs, aiming to drive procedure growth in Q4 2025 and beyond.